Schedule 13G ownership disclosure

AN2 Therapeutics, Inc.

Common Stock, par value $0.00001 per share · CUSIP: 037326105

Event date: 2026-03-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Vivo Opportunity Fund Holdings, L.P.

    Shares: 2,864,346.00 · Class: 8.0%

  • Vivo Opportunity, LLC

    Shares: 2,864,346.00 · Class: 8.0%

  • Vivo Opportunity Cayman Fund, L.P.

    Shares: 289,294.00 · Class: 0.8%

  • Vivo Opportunity Cayman, LLC

    Shares: 289,294.00 · Class: 0.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-26-027660
Form type
SCHEDULE 13G
Filer
AN2 Therapeutics, Inc.
CIK
CIK 1880438
Filed
Mar 13, 2026
Reporting period
Mar 10, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub